Areas of Focus:

Academia–Industry PartnershipsAdaptive ImmunityAnimal ModelsB Cell BiologyBiological & MechanisticCollaboration & InnovationCross-institutional CollaborationExperimental Platforms & ModelsFunctional Genomics & CRISPRImmunometabolismIn Vitro ModelsSingle Cell TechnologiesT Cell BiologyCrohn's DiseaseGastrointestinal DiseasesMultiple SclerosisNeurologic DiseasesSjögren’s DiseaseSystemic DiseasesUlcerative Colitis
  • Vice Chair for Research, Department of Pathology, NYU Grossman School of Medicine / NYU Langone Health
  • Jeffrey Bergstein Professor of Medicine, Department of Pathology, NYU Grossman School of Medicine / NYU Langone Health
  • Director, Ion Channels & Transporters in Immunity (ICTI) Program, NYU Langone Health

Dr. Stefan Feske holds the Jeffrey Bergstein Professorship in Medicine and serves as Vice Chair for Research in the Department of Pathology, Director of the Ion Channels & Transporters in Immunity (ICTI) program, and Co-Director of the Translational Immunology Center (TrIC) at NYU Grossman School of Medicine. He earned his medical degree from the University of Freiburg, Germany, and completed postdoctoral training at the Max Planck Institute for Immunobiology and the Immune Disease Institute at Harvard Medical School.

Dr. Feske has made landmark contributions to the field of calcium signaling in immunity. He was central to identifying ORAI1 as the pore-forming subunit of the CRAC channel and to characterizing the first patients with ORAI1 and STIM1 mutations — work that defined a novel disease entity now known as CRAC channelopathy. His laboratory has since deepened our understanding of how CRAC channels shape lymphocyte function, influencing gene expression and cellular metabolism across a broad range of immune contexts, including infection, cancer, autoimmunity, and allergy. More broadly, the Feske lab investigates ion channels, transporters, and ionic signaling pathways that regulate immune responses in both health and disease.

This foundational work has driven the development of CRAC channel inhibitors as a new class of immunotherapeutic agents. Dr. Feske is a scientific co-founder of CalciMedica, a biotechnology company advancing CRAC channel inhibitors through clinical trials.

Projects

Featured Pilot Projects

Copper Transporter SLC31A1 in Th17 Cells and Multiple Sclerosis
Project | New York University

Copper Transporter SLC31A1 in Th17 Cells and Multiple Sclerosis

Investigating how copper transport via SLC31A1 regulates pro-inflammatory Th17 cell activity, this project uncovers a novel link between immune cell metabolism and MS, pointing toward new therapeutic targets.